| abstract |
The invention illustrates a drug for treatment of myoma of the uterus that enables preservation of biological and sexual properties of the women and does not provoke contraindications accompanying other known methods of treatment. The invention is represented by a mixture of two substances methotrexate and L-arginine. The drug for treatment of myoma of the uterus is composed of 5 g methotrexate and 10 g L-arginine with 985 cm3 water. Combination of two substances in aqueous solution yields a homogenous mixture where each of the components preserves its own chemical identity. The drug is applied on the eighth day of the follicular phase of the menstrual cycle of patients with myoma of the uterus. The patient is placed into lythotomy position, the vaginal speculum is placed and the uterine cervix is pulled with roller forceps so that the external uterine cervix is exposed. The package is open, the puncture needle iS inserted into the cervical channel and is directed to the myometrium towards the side at which myoma is located. The needle is pushed through the endometrium to the depth of 1 cm. It is necessary to be sure to inject the drug at 1 cm depth to avoid possible penetration through the uterine wall. We aspirate to check that the needle is not inside a blood vessel, and after that inject the drug slowly. The syringe and needle are discarded after use. The mixture is applied in three consecutive menstrual cycles. The method is simple, feasible on out-patient basis by practicing gynecologist; no ultrasonografic guidance is needed; transvaginal and transcervical approach is used. The mixture induces the process of apoptosis (programmed cell death) so that no necrosis, degeneration or inflammation are provoked if all antisepsis precautionary measures are applied. Dramatic reduction of both loss of blood during menstruation in women with myoma and the volume of myoma are evidenced. Since the dose applied is very low, toxicity is negligible. Application of this mixture gradually leads to menopause without disturbance of the hypothalamo-pituitary-gonadal axis. Application of this mixture does not provoke early or late complication specific for other medical approaches listed in the background of the invention. After completion of therapy with this medication, the volume of myoma is reduced by 20-30% and no surgical removal is required. After such therapy myoma does not grow any longer. After the therapy menstrual bleedings become normal in volume. |